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Introduction: Although patients with non-small cell lung cancer
(NSCLC) whose tumors harbor epidermal growth factor receptor
(EGFR) activating mutations commonly experience significant re-
gressions when treated with erlotinib or gefitinib, they uniformly
develop resistance to these agents. The secondary EGFR T790M
mutation is found in 50% of patients with acquired resistance.
Herein, we studied XL647, an oral small molecule inhibitor of
multiple receptor tyrosine kinases, including EGFR, VEGFR2,
HER2, and EphB4, in NSCLC patients known or suspected of
having tumors harboring T790M.
Methods: Eligible patients included those with relapsed or recurrent
advanced NSCLC who progressed after12 weeks of stable disease
or response to erlotinib or gefitinib and/or those patients with a
documented EGFR T790M. XL647 300 mg was administered once
daily. The primary end point was objective response rate. Pretreat-
ment plasma samples were collected for mutation testing of circu-
lating tumor DNA.
Results: Forty-one patients were enrolled; 33 were evaluable for
efficacy. One partial response was observed (response rate 3% and
90% confidence interval, 0% to 14%). Of patients whose tumors
harbored T790M, 67% (8/12) had progression of disease as best
response compared with 14% (3/21) of those without this mutation.
Plasma samples from 40 patients were available for mutation testing,
14 (35%) of which were found to have EGFR mutations.
Conclusions: The 3% response rate observed did not meet the pre-
specified threshold to recommend further study of XL647 in patients
who develop acquired resistance to erlotinib or gefitinib. Patients with
T790M had a significantly worse progression-free survival.
Key Words: EGFR-sensitizing mutation, EGFR-resistance muta-
tion, Tyrosine kinase inhibitors, Acquired resistance, Molecular
analysis.
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Somatic epidermal growth factor receptor (EGFR) muta-tions in patients with non-small cell lung cancer (NSCLC)
have been identified as the basis of sensitivity to the EGFR
tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib.1–3
The most prevalent mutations consist of deletions of exon 19
and a point mutation (L858R) in exon 21, which together
comprise 90% of all EGFR kinase domain mutations.1–3
Randomized phase III studies of patients with metastatic
NSCLC and EGFR mutations have demonstrated improved
progression-free survival and response rates for treatment
with gefitinib compared with conventional doublet chemo-
therapy.4–6 Based on these data, EGFR TKIs have emerged
as an option for first line therapy in patients with EGFR-
sensitizing mutations.
Despite these promising results, patients with EGFR-
mutant NSCLC inevitably develop progression of disease
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while receiving erlotinib or gefitinib, which has been de-
scribed as “acquired resistance.” Two different mechanisms
of acquired resistance have been described:50% of patients
develop a secondary mutation in EGFR (T790M in exon 20)
and 10% of patients have amplification of the oncogene
MET.7–13 Although T790M is associated with better out-
comes after acquired resistance,13 there are no proven thera-
pies in this patient population. Multiple “second generation”
EGFR TKIs directed at overcoming acquired resistance are
under study. XL647 is an inhibitor of EGFR, HER2/ErbB2,
vascular endothelial growth factor receptor-2, and EphB4.14
In tumor xenografts using the H1975 cell line, which harbors
both the EGFR L858R and T790M mutations, XL647 shows
a minimal inhibitory concentration (IC50 of 0.92 mol) that is
more than 10-fold lower than that observed with erlotinib
(IC50 of 16.14 mol) or gefitinib (IC50 of 10.41 m).14 In a
phase II trial of XL647 in patients with untreated NSCLC,
clinical characteristics were used to enrich for those most
likely to respond to EGFR TKIs.15 In that setting, XL647 was
found to have a 28% partial response rate and an 88% overall
response rate in patients with documented EGFRmutations.15
We hypothesized that XL647 would lead to meaningful
disease stabilization or partial response in patients with ac-
quired resistance to erlotinib or gefitinib. To test this hypoth-
esis, we undertook an open label, multi-institutional phase II
study assessing the efficacy and safety of XL647 in patients
with NSCLC who achieved stable disease or better after at
least 12 weeks of treatment with erlotinib or gefitinib and
who subsequently progressed or whose tumors harbored an
EGFR exon 20 T790M resistance mutation.
MATERIALS AND METHODS
Patient Eligibility Criteria
All patients had unresectable stage IIIB, stage IV, or
recurrent pathologically confirmed NSCLC and had radio-
graphic or clinical progression of disease following previous
treatment with at least 12 weeks of erlotinib or gefitinib
administered as a single agent or in combination with bevaci-
zumab and investigator-declared response (including stable dis-
ease) or a documented T790M mutation. Inclusion required
Eastern Cooperative Oncology Group performance status of 0 or
1 and measurable disease as per RECIST version 1.0.16 Patients
were excluded if they had progressive, symptomatic, or hemor-
rhagic brain or leptomeningeal metastases.
This trial was reviewed and approved by the Institu-
tional Review Board of each center; all patients provided
written informed consent. Data were collected and analyzed
centrally at Exelixis, with direct inspection and review of all
lead investigators.
Treatment
Patients were treated with 28 day cycles of XL647 300
mg (six 50 mg tablets) daily.17 XL647 was continued until the
development of unacceptable toxicity or progression of dis-
ease. Grade 3 or 4 toxicities believed to be possibly related to
XL647 were managed with dose interruptions until resolution
to grade 1 or baseline values. Two dose reductions were
permitted per patient (250 and 200 mg). Removal from study
occurred if toxicities did not resolve within 21 days.
Study Evaluation
Patients had clinical evaluation (history, physical ex-
amination, electrocardiograms, complete blood count, com-
prehensive metabolic panel, and urinalysis) every 2 weeks for
the first 2 months and monthly thereafter. All toxicities were
graded using National Cancer Institute Common Terminology
Criteria for Adverse Events version 3.0. Computed tomography
scans of all sites of measurable disease were obtained at baseline
and approximately every 8 weeks thereafter. Responses were
determined using RECIST version 1.0.16
Genotyping of Tumor and Plasma DNA
DNA from available tumor samples at initial diagnosis
was analyzed for the presence of EGFR mutations at different
institutions using standard methods (direct sequencing, poly-
merase chain reaction [PCR]-single strand conformation
polymorphism,18 PCR-RFLP,19 or Scorpion Amplification
Refractory Mutation system [SARMS]20).21 When available,
tissue samples obtained after progression of disease on erlo-
tinib or gefitinib were analyzed for the presence of EGFR
mutations, including T790M.
Mutational analysis of free circulating plasma DNA
was evaluated in this study. Plasma samples were analyzed
by DxS Ltd. (Manchester, United Kingdom) using SARMS
technology.20 The assay detects common alterations in exons
18, 19, 20, and 21. Plasma samples collected on day 1 before
the initiation of XL647 were typically analyzed.
Pharmacokinetics
Plasma pharmacokinetic samples were collected at pre-
dose and/or at postdose on cycle 1 days 1 and 15, cycle 2 days
1 and 15, cycle 3 day 1, and approximately every 2 cycles (8
weeks) after cycle 3 day 1. At each time point, blood was
collected into potassium EDTA and separated by centrifuga-
tion; and plasma was frozen. The concentration of XL647
was measured in each sample using liquid chromatography
coupled with tandem mass spectrometry.
Statistical Analysis
The primary end point was overall response rate (com-
plete response and partial response). Secondary endpoints
were progression-free survival, overall survival, and evalua-
tion of safety and tolerability. A Simon two-stage design was
used, with stage 1 enrolling up to 20 subjects to ensure 15
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evaluable patients. If there was 1 responder out of 15
evaluable patients, an additional 20 subjects would be ac-
crued to enroll at least 30 evaluable subjects. If a total of 3 or
more confirmed responses were observed in the study, further
study of XL647 would be warranted. If the true response rate
was 15% or greater, there would be at least an 80% proba-
bility of observing three or more responses.
The Kaplan-Meier method was used to estimate pro-
gression-free survival and overall survival. For progression-
free survival, patients were censored at the start of any other
anticancer therapy, date of last contact, or analysis cutoff
date. For overall survival, patients were censored at date of
last contact or analysis cutoff date.
For pharmacokinetic studies, descriptive statistics (e.g.,
median, range, mean, standard deviation, and/or percent co-
efficient of variation) were calculated from individual subject
concentration-time data after grouping by day and hour.
RESULTS
Baseline Characteristics
Between June 29, 2007, and March 4, 2008, 41 patients
were enrolled. Baseline characteristics for patients are listed
in Table 1. Investigator reported best response to erlotinib or
gefitinib therapy had been complete response (n  3), partial
response (n  27), stable disease (n  10), and disease
progression (n  1). The patient with progression of disease
as best response to an EGFR TKI had a documented T790M
mutation. The median number of years since diagnosis and
initiating XL647 was 2 (range, 0.9 to 15). Twenty-four
percent of patients (n  10) received chemotherapy between
first-generation TKI therapy and enrollment.
Treatment
All patients received at least one cycle of XL647
(median cycles, 3 and range, 1 to 23). Patients remained on
XL647 for a median of 64 days (range, 23–622 days).
Efficacy
Thirty-three patients were evaluable for efficacy. Eight
patients were not evaluable for efficacy: two experienced
early serious adverse events (one with grade 3 nausea, vom-
iting, and diarrhea; one with grade 2 ventricular arrhythmia);
one developed rapid clinical deterioration and did not un-
dergo imaging evaluation; and five stopped treatment early
secondary to progression of disease (range, 28–57 days).
Because tumor measurements were not available for the five
patients with early progression of disease, they were deemed
inevaluable for efficacy (Figure 1).
One partial response was observed (response rate 3%,
90% confidence interval [CI], 0% to 14%; Figure 2). Stable
disease was observed in 21 patients (64%). Eleven patients
(33%) had disease progression as the best response. Median
progression-free survival for the 33 evaluable patients was
3.5 months (range, 0.5–17.3 months; 90% CI, 2.8 to 5.5;
Supplemental Figure 1A, http://links.lww.com/JTO/A148).
Median overall survival for all treated patients was 16.1
months (90% CI, 9.8 to not reached, as not enough
TABLE 1. Baseline Patient Characteristics (N  41)
Characteristic N
Gender
Male 10
Female 31
Age (yr)
Median 62.5
Range 27–90
ECOG performance status
0 18
1 23
Race/ethnicity
White 22
Asian 14
Black/African American 3
Hispanica 1
Not reported 1
Histology
Adenocarcinoma 37
Adenocarcinoma with BAC 1
Squamous cell carcinoma 1
NSCLCb 2
Smoking historyc
Never 30
Former 10
Current 1
Years since diagnosis
Median 2
Range 0.9–15
Sites of metastases, % of patientsd
Lung 59
Bone 37
Lymph node 22
Liver 20
Brain 15
Othere 17
Number of prior regimens (N  38)f
Median 3
Range 1–7
Prior tyrosine kinase inhibitors
Erlotinib alone 29
Gefitinib alone 3
Erlotinib and gefitinib 6
Erlotinib and bevacizumab 3
Duration of time receiving tyrasine kinase inhibitors
Median (months) 22
Range (months) 4–109
Time between tyrosine inhibitor and XL647
Median (d) 41
Range (d) 13–372
a Patient indicates race as White.
b NSCLC not further classified.
c Of the 11 former and current smokers, the median number of pack years was 20
(range, 2 to 125).
d Patients could have had more than one site of metastasis, thus percentages do not
add up to 100%.
e Other includes pleura, pericardium, adrenal, lung, and bone.
f Detailed chemotherapy regimens are available for only 38 patients, 10 of which
did not receive any traditional cytotoxic chemotherapy, only an EGFR tyrosine kinase
inhibitor with stable disease (n  1) or partial response (n  9).
ECOG, Eastern Cooperative Oncology Group; BAC, bronchoalveolar features;
NSCLC, non-small cell lung cancer.
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events have been observed; Supplemental Figure 1B,
http://links.lww.com/JTO/A148). One-year survival was 54%.
The patient with a partial response was an Asian
woman whose tumor harbored an exon 19 deletion without a
T790M mutation at the time of diagnosis. She initially was
treated with erlotinib for 17 months with a complete re-
sponse. On progression of disease, erlotinib was discontinued
and chemotherapy was administered. She had not received an
EGFR TKI in 11 months before initiating treatment with
XL647. The patient developed disease progression after 8
months of XL647 therapy. As the patient did not undergo
rebiopsy after treatment with XL647, the presence of T790M
was unknown.
Toxicity
Table 2 lists the most common treatment-related toxic-
ities. Eleven patients (28%) required a dose reduction for
toxicity, most commonly for diarrhea (27%) and rash (18%).
Eight serious adverse events that occurred in four patients
were thought to be related to XL647. One patient experienced
five events of grade 3 severity: diarrhea (two events), abdom-
inal pain, nausea, and vomiting; XL647 was discontinued.
One patient each had grade 4 bilateral pulmonary emboli
(XL647 discontinued); grade 3 ventricular arrhythmia
(XL647 discontinued); and grade 3 QTc prolongation (patient
asymptomatic). In addition to the three patients described in
whom XL647 was discontinued, the drug was stopped in
three other patients for an adverse event related to the study
agent and in one patient for a serious adverse event not
related to XL647, totaling 7 (17%). There were no treatment-
related deaths.
Molecular Characteristics
Tumor mutation status was known in 21 of 41 patients
(51%) (Figure 3 and Supplemental Table 1, http://links.lww.
com/JTO/A149). Plasma samples from 40 patients were
tested for EGFR mutations using SARMS,20 with the excep-
tion of two specimens examined with single molecule se-
quencing. One patient did not have plasma available for
EGFR mutation testing. Fourteen (35%) were found to have
EGFR mutations (Supplemental Table 2, http://links.lww.
FIGURE 1. Diagram for this phase II trial us-
ing XL647 in patients who have progressed
after erlotinib or gefitinib. TKI, tyrosine kinase
inhibitors; SD, stable disease; CR, complete re-
sponse; PR, partial response; POD, progression
of disease.
FIGURE 2. Waterfall Plot. The best-calculated
responses based on measurable lesions for the 33
evaluable patients. Mutation status is based on
analysis of available tumors. ‡EGFR-sensitizing mu-
tation is exon 19 deletion for these two patients.
Overall response indicated on horizontal axis.
*PD, based on appearance of new lesions. EGFR
T790M unknown mutation status refers to those
patients with tumors harboring EGFR-sensitizing
mutations who did not undergo rebiopsy at the
time of progression of disease either after the first-
generation TKIs or XL647. SD, stable disease; PD,
progression of disease; and PR, partial response.
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com/JTO/A149). T790M mutations were identified in 10 of
the 40 plasma specimens (25%), 2 of which were detected
using single molecule sequencing.22 Of the 14 plasma sam-
ples in which EGFR mutations were detected, 10 had T790M
mutations. T790M without a corresponding activating muta-
tion was detected in one plasma sample. Supplemental Table
1 (http://links.lww.com/JTO/A149) summarizes the results
for the mutational analyses from tumor and plasma for all
patients. For the 20 patients whose tumor EGFR mutation
status was known, analysis of the corresponding plasma DNA
samples revealed the same EGFR mutations in 6 samples,
whereas no plasma EGFR mutation was detected in 14
samples; thus, a sensitivity rate of 30%. By analyzing plasma
DNA, EGFR mutations were identified in an additional eight
patients with unknown tumor mutation status. Therefore,
EGFR mutation status was known in a total of 28 of 40
patients (70%).
In the 33 evaluable patients, 12 were found to have
T790M mutations in tissue samples (n  5), plasma (n  6),
or both (n  1). In an exploratory analysis, progression of
disease as best response was noted in 67% (8/12) of patients
whose tumors or plasma contained T790M, compared with
14% (3/21) of those that did not have this resistance
mutation. A multivariate Cox regression analysis showed
that the presence of T790M was a significant predictor of
shorter progression-free survival in patients treated with
XL647, with median progression-free survival of 1.8
months (90% CI, 1.8 –2.8) compared with median survival
of 5.5 months (90% CI, 3.7–7.5) in those in whom a
T790M mutation was not detected (p  0.0044; Supple-
mental Figure 2, http://links.lww.com/JTO/A150). The co-
variates in this analysis included gender, age, baseline ECOG
score, smoking history, years since initial diagnosis, years
since metastases, years on any therapy, years on first gener-
ation TKI, and presence/absence of an EGFR-activating mu-
tation, and baseline plasma DNA level (data not shown).
Pharmacokinetics
All patients had measurable XL647 concentrations.
Steady state appeared to have been achieved by cycle 1 day
15, with a median predose concentration of 439 ng/mL (0.89
M; Figure 4). The fluctuation between peak (i.e., 3–6 hours
postdose) and trough (predose) concentrations was small at
steady state. Exposure to XL647 was maintained over re-
peated cycles of dosing with XL647.
DISCUSSION
This phase II study of XL647 was designed to assess
the efficacy and safety of this TKI in patients with advanced
NSCLC who progressed following previous treatment with at
least 12 weeks of erlotinib or gefitinib administered as a
single agent or in combination with bevacizumab and inves-
tigator-declared response (including stable disease), or whose
tumors harbored an EGFR exon 20 T790M resistance muta-
tion. Although relatively well tolerated, XL647 had insuffi-
cient antitumor activity to warrant further evaluation. In this
study, the presence of T790M mutation was associated with
more rapid tumor progression compared with patients without
T790M. Diagnostic (pre-TKI) and/or “acquired resistance”
genotype biopsy samples were evaluable for mutation status
in 51% of patients. Analysis of plasma DNA allowed detec-
tion of mutation status in another 20%.
The response rate of XL647 in this study was 3%, a
stark contrast to the findings of the “up-front” study where
XL647 resulted in a 28% partial response rate in a patient
population with untreated NSCLC, phenotypically enriched
for EGFR-sensitizing mutations.15 Several explanations may
account for the differences seen in response to XL647 be-
tween these two cohorts of patients. One possibility is that the
drug does not achieve concentrations sufficient to inhibit
T790M in those patients with acquired resistance compared
with those patients who are EGFR TKI-naive with classic
EGFR mutations. In this study, the one patient with a partial
response to XL647 was a young woman whose tumor har-
bored an exon 19 deletion without a T790M mutation and
who had a complete response to erlotinib. Before initiating
treatment with XL647, she had not received an EGFR TKI in
nearly 11 months. The response to XL647 in this patient may
demonstrate a second treatment response that would have
occurred with another EGFR TKI, as noted by others.23–26
Finally, the patients included in this study represented a
heterogeneous group, only a subset of whom would likely
meet the consensus criteria for the clinical state of acquired
resistance.27
The propensity to develop T790M-mediated resis-
tance may differ among distinct EGFR TKIs, as seen in
preclinical studies.28 Chmielecki et al engineered acquired
resistance in vitro with XL647 and erlotinib by exposing
the EGFR mutant TKI-sensitive PC-9 cells (lung adenocar-
TABLE 2. Related Adverse Events (N  41)
Any
N (%)
Grade 1
N (%)
Grade 2
N (%)
Grade 3
N (%)
Adverse eventa
Diarrhea 33 (80) 21 (51) 3 (7) 9 (22)
Rashb 26 (63) 15 (37) 11 (27) 0 (0)
Nausea 13 (32) 10 (24) 2 (5) 1 (2)
Fatigue 12 (29) 9 (22) 2 (5) 1 (2)
QTc prolongation 11 (27) 4 (10) 6 (15) 1 (2)
Dry skin 11 (27) 9 (22) 2 (5) 0 (0)
Hypertension 5 (12) 1 (2) 3 (7) 1 (2)
ALT, elevated 5 (12) 3 (7) 0 (0) 2 (5)
AST, elevated 5 (12) 3 (7) 1 (2) 1 (2)
Creatinine, elevated 4 (10) 1 (2) 2 (5) 1 (2)
Dry mouth 4 (10) 3 (7) 1 (2) 0 (0)
Abdominal pain 4 (10) 3 (7) 0 (0) 1 (2)
Weight, decrease 4 (10) 4 (10) 0 (0) 0 (0)
Anorexia 3 (7) 3 (7) 0 (0) 0 (0)
Cough 3 (7) 2 (5) 1 (2) 0 (0)
Dysgeusia 3 (7) 2 (5) 1 (2) 0 (0)
Vomiting 3 (7) 2 (5) 0 (0) 1 (2)
Hypomagnesemia 3 (7) 2 (5) 1 (2) 0 (0)
a Adverse events graded using the NCI Common Terminology for Adverse Events
Version 3.
b Rash includes rash, dermatitis acneiform, and desquamation.
QTc, corrected QT interval; ALT, alanine aminotransferase; AST, aspartate
aminotransferase.
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FIGURE 3. Tumor mutation analysis. Mutation status was known in 21 patients. ¶Two of twenty-one patients underwent bi-
opsy at diagnosis and after TKI therapy, for a total of 23 tumor specimens. Thirteen patients had tumors sampled before initi-
ating erlotinib or gefitinib. §One patient underwent biopsy before initiating erlotinib or gefitinib and subsequent to disease
progression with these first-generation TKIs; the tumor harbored an EGFR exon 21 L858R-activating mutation and a T790M
resistance mutation. ‡One patient had tumor sampled before initiating erlotinib or gefitinib and after disease progression with
XL647; the tumor harbored an EGFR exon 19 deletion activating mutation and a T790M resistance mutation. Seven patients
had tumors sampled only after progression of disease with erlotinib or gefitinib. One patient only underwent biopsy subse-
quent to disease progression with XL647. A total of eight tumors were found to have T790M mutations. ¥Germline T790M
mutation. *This T790M was found in the patient whose primary activating mutation was not detected. EGFR, epidermal
growth factor receptor.
FIGURE 4. Pharmacokinetics. XL647 accumu-
lated in plasma with repeated daily dosing.
Steady state was achieved by about cycle 1 day
15, where the median plasma predose concentra-
tion was 439 ng/mL (0.89 M). Predose and
postdose concentrations are shown with the me-
dian (yellow bar), interquartile range (box), and
range (whiskers). Exposure to XL647 was main-
tained over repeated cycles of dosing with XL647,
as can be seen from the small number of patients
with available PK data obtained after three cycles.
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cinoma, del E746_A750) to increasing concentrations of
drug. Direct sequencing showed that erlotinib-resistant cell
lines harbored T790M, whereas XL647-resistant cells did
not. These XL647-resistant cells remained intermediately
sensitive to erlotinib.28 Furthermore, five patients from the
phase II clinical trial using XL647 first line in NSCLC who
benefited from the drug and subsequently developed acquired
resistance underwent rebiopsy, and only one was found to
harbor the EGFR T790M mutation. Taken together, this
suggests that although first-line XL647 treatment of EGFR-
mutant lung cancer may result in non-T790M-mediated ac-
quired resistance, the drug is largely ineffective in the treat-
ment of T790M-mediated acquired resistance once it has
developed.
In this study, we explored the ability to detect EGFR
mutation status in plasma, including the presence of T790M,
given that it contains elevated tumor-derived DNA. Tumor
specimens represent the gold standard for EGFR mutation.
Nevertheless, there are barriers to obtaining samples for the
serial monitoring of genotypes during the use of targeted
therapies, including the timeliness and feasibility of rebiopsy
procedure, the increased complication risks, and the acquisi-
tion of adequate cancer cells for such studies. Herein, tumor
EGFR mutation status was known in 20 of 41 patients, and
only 8 of the patients had undergone rebiopsy on progression
of disease after the TKIs, erlotinib or gefitinib. Plasma spec-
imens from 40 patients were tested for EGFR mutations just
before initiating XL647. Analysis of corresponding plasma
DNA and tumor biopsy samples revealed the same EGFR
mutations in only six patients; thus, a 30% sensitivity rate in
plasma. Similar results using SARMS technology were ob-
tained in a recent study analyzing EGFR mutations in free
plasma DNA samples of patients with metastatic NSCLC.29
This assay has several limitations. Mutant DNA needs to
comprise 1% of the total DNA to be easily detected; only
known DNA aberrations can be identified; insertions and
deletions of DNA cannot be comprehensively distinguished;
and it has been associated with false-positive results in certain
situations.21 Alternative methods of identifying EGFR-acti-
vating mutations have led to higher concordance between
plasma and tumor, including mutant-enriched PCR, micro-
fluidics-based digital PCR techniques, and the combination of
SARMS and HPLC/WAVE with whole genome amplifica-
tion.30–32 Nevertheless, to be able to use free plasma DNA for
the detection of mutations in the clinic, we will need to
develop assays that are reliable, quick, and accurate, and
which can be standardized.
Results from two large clinical studies evaluating the
second generation EGFR TKIs, neratinib (HKI-272) and
afatinib (BIBW-2992), both irreversible inhibitors of EGFR
and HER2, recently have been reported.33–35 Similar to our
results, neratinib had limited activity in patients with previous
benefit from first-generation tyrosine kinase therapy who
developed acquired resistance. The low response rate was
thought to be due to insufficient drug levels.33 Afatinib was
compared with placebo in patients who progressed after 12
weeks of treatment with either erlotinib or gefitinib in a
randomized phase IIb/III study. Although the primary objec-
tive of improvement in overall survival was not reached
(HR  1.077; 95% CI, 0.862–1.346; p  0.743), afatinib
demonstrated a higher overall response rate (p  0.01),
disease control rate at 8 weeks (p  0.0001), improved
progression-free survival (p  0.0001), and an improvement
in cancer-related symptoms (cough, dyspnea, and pain) when
compared with placebo.34,35 Furthermore, patients who had
had previous clinical benefit to erlotinib or gefitinib for 6
months (complete response, partial response, and stable disease),
and a short interval between previous erlotinib or gefitinib (4
weeks) and no interval chemotherapy, had a median progres-
sion-free interval of 4.5 months compared with 1.0 month for
those on the placebo arm.35 Thus, afatinib has potential useful-
ness in the patient population that meets the consensus criteria
for the clinical state of acquired resistance.27,34,35
In summary, this phase II open label, multi-institutional
study of XL647, a second generation EGFR inhibitor, did not
meet the predetermined criteria of a 10% response rate in
patients with NSCLC who had progressed after responding to
treatment with erlotinib or gefitinib. XL647 was not able to
effectively treat T790M-mediated resistance, and the pres-
ence of this resistance mutation was a significant predictor of
shorter progression-free survival in this group; thus, further
development of this agent in patients whose tumors harbor
T790M is not indicated. Additional studies are needed to find
agents that will inhibit the EGFR exon 20 T790M mutation
and prolong survival in these patients.
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